دورية أكاديمية
أعرض في EDS

Comparative Proteomics Analysis of Urine Reveals Down-Regulation of Acute Phase Response Signaling and LXR/RXR Activation Pathways in Prostate Cancer.

التفاصيل البيبلوغرافية
العنوان: Comparative Proteomics Analysis of Urine Reveals Down-Regulation of Acute Phase Response Signaling and LXR/RXR Activation Pathways in Prostate Cancer.
المؤلفون: Davalieva K; Research Centre for Genetic Engineering and Biotechnology 'Georgi D Efremov', Macedonian Academy of Sciences and Arts, Skopje, Krste Misirkov 2, 1000 Skopje, Macedonia. katarina@manu.edu.mk., Kiprijanovska S; Research Centre for Genetic Engineering and Biotechnology 'Georgi D Efremov', Macedonian Academy of Sciences and Arts, Skopje, Krste Misirkov 2, 1000 Skopje, Macedonia. skiprijanovska@manu.edu.mk., Maleva Kostovska I; Research Centre for Genetic Engineering and Biotechnology 'Georgi D Efremov', Macedonian Academy of Sciences and Arts, Skopje, Krste Misirkov 2, 1000 Skopje, Macedonia. maleva_i@manu.edu.mk., Stavridis S; University Clinic for Urology, University Clinical Centre 'Mother Theresa', 1000 Skopje, Macedonia. sotir.stavridis@medf.ukim.edu.mk., Stankov O; University Clinic for Urology, University Clinical Centre 'Mother Theresa', 1000 Skopje, Macedonia. oliver.stankov@medf.ukim.edu.mk., Komina S; Institute of Pathology, Medical Faculty, University 'St. Cyril and Methodius', 1000 Skopje, Macedonia. s_komina@yahoo.com., Petrusevska G; Institute of Pathology, Medical Faculty, University 'St. Cyril and Methodius', 1000 Skopje, Macedonia. gordanap61@yahoo.com., Polenakovic M; Research Centre for Genetic Engineering and Biotechnology 'Georgi D Efremov', Macedonian Academy of Sciences and Arts, Skopje, Krste Misirkov 2, 1000 Skopje, Macedonia. momir@manu.edu.mk.
المصدر: Proteomes [Proteomes] 2017 Dec 29; Vol. 6 (1). Date of Electronic Publication: 2017 Dec 29.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG, Multidisciplinary Digital Publishing Institute Country of Publication: Switzerland NLM ID: 101621966 Publication Model: Electronic Cited Medium: Print ISSN: 2227-7382 (Print) Linking ISSN: 22277382 NLM ISO Abbreviation: Proteomes Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, Multidisciplinary Digital Publishing Institute, [2013]-
مستخلص: Detecting prostate cancer (PCa) using non-invasive diagnostic markers still remains a challenge. The aim of this study was the identification of urine proteins that are sufficiently sensitive and specific to detect PCa in the early stages. Comparative proteomics profiling of urine from patients with PCa, benign prostate hyperplasia, bladder cancer, and renal cancer, coupled with bioinformatics analysis, were performed. Statistically significant difference in abundance showed 20 and 85 proteins in the 2-D DIGE/MS and label-free LC-MS/MS experiments, respectively. In silico analysis indicated activation, binding, and cell movement of subset of immune cells as the top affected cellular functions in PCa, together with the down-regulation of Acute Phase Response Signaling and Liver X Receptor/ Retinoid X Receptor (LXR/RXR) activation pathways. The most promising biomarkers were 35, altered in PCa when compared to more than one group. Half of these have confirmed localization in normal or PCa tissues. Twenty proteins (CD14, AHSG, ENO1, ANXA1, CLU, COL6A1, C3, FGA, FGG, HPX, PTGDS, S100A9, LMAN2, ITIH4, ACTA2, GRN, HBB, PEBP1, CTSB, SPP1) are oncogenes, tumor suppressors, and multifunctional proteins with highly confirmed involvement in PCa, while 9 (AZU1, IGHG1, RNASE2, PZP, REG1A, AMY1A, AMY2A, ACTG2, COL18A1) have been associated with different cancers, but not with PCa so far, and may represent novel findings. LC-MS/MS data are available via ProteomeXchange with identifier PXD008407.
Competing Interests: The authors have declared that they have no conflict of interests.
References: J Immunol. 2004 Apr 1;172(7):4470-9. (PMID: 15034063)
Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2015;36(1):5-36. (PMID: 26076772)
J Clin Invest. 1932 Jul;11(4):677-82. (PMID: 16694069)
Cancer Res. 2004 Mar 15;64(6):2212-21. (PMID: 15026365)
Nat Rev Cancer. 2015 Apr;15(4):216-24. (PMID: 25786697)
N Engl J Med. 2004 May 27;350(22):2239-46. (PMID: 15163773)
Science. 2015 Jan 23;347(6220):1260419. (PMID: 25613900)
Matrix Biol. 2014 Jul;37:131-41. (PMID: 24657887)
J Biol Chem. 2011 Jun 10;286(23 ):20637-47. (PMID: 21489984)
Mol Cancer Res. 2010 Nov;8(11):1453-65. (PMID: 20870736)
Proteomics Clin Appl. 2010 Apr;4(4):464-78. (PMID: 21137064)
Cell Death Differ. 2006 Jan;13(1):12-9. (PMID: 16179938)
Nature. 2011 Feb 10;470(7333):269-73. (PMID: 21289624)
Nature. 2008 Apr 3;452(7187):571-9. (PMID: 18385731)
J Urol. 1995 Aug;154(2 Pt 1):407-13. (PMID: 7541857)
Immunol Cell Biol. 2005 Oct;83(5):462-7. (PMID: 16174094)
BJU Int. 2013 Oct;112(6):717-28. (PMID: 22759214)
Nucleic Acids Res. 2013 Jan;41(Database issue):D1063-9. (PMID: 23203882)
Mol Cell Proteomics. 2008 Oct;7(10):1850-62. (PMID: 18667409)
Anal Chem. 2009 Dec 1;81(23):9819-23. (PMID: 19839595)
Curr Opin Oncol. 2014 May;26(3):259-64. (PMID: 24626128)
J Biol Chem. 2000 Feb 25;275(8):5958-65. (PMID: 10681589)
Annu Rev Med. 2009;60:139-51. (PMID: 18947298)
Urology. 1998 May;51(5A Suppl):141-5. (PMID: 9610570)
Biochim Biophys Acta. 2011 Aug;1812(8):982-94. (PMID: 21193033)
CA Cancer J Clin. 2015 Sep-Oct;65(5):339-44. (PMID: 26208318)
PLoS One. 2015 Jul 24;10(7):e0133773. (PMID: 26208298)
J Natl Cancer Inst. 2009 Mar 18;101(6):374-83. (PMID: 19276453)
J Sep Sci. 2007 Aug;30(12):1979-88. (PMID: 17638362)
J Immunol. 1991 Sep 1;147(5):1567-74. (PMID: 1880416)
Clin Biochem. 2013 Apr;46(6):524-38. (PMID: 23266295)
Urol Clin North Am. 2016 Feb;43(1):17-38. (PMID: 26614026)
Crit Rev Oncog. 2014;19(6):455-68. (PMID: 25597355)
PLoS One. 2012;7(2):e30885. (PMID: 22355332)
Electrophoresis. 2012 Jul;33(12):1855-62. (PMID: 22740474)
Lancet. 2001 Feb 17;357(9255):539-45. (PMID: 11229684)
J Proteome Res. 2011 Mar 4;10(3):1361-73. (PMID: 21166384)
Clin Cancer Res. 2005 Jul 15;11(14):5146-52. (PMID: 16033829)
Adv Cancer Res. 2009;105:1-19. (PMID: 19879420)
Pharmacogenomics. 2007 Mar;8(3):237-55. (PMID: 17324112)
Adv Exp Med Biol. 2014;772:229-62. (PMID: 24272362)
Biomark Cancer. 2016 May 05;8(Suppl 2):15-33. (PMID: 27168728)
Biochem Pharmacol. 2015 Mar 15;94(2):53-62. (PMID: 25593038)
J Proteomics. 2010 Sep 10;73(10):1839-50. (PMID: 20398807)
Ann Surg Oncol. 2015 Jul;22(7):2439-45. (PMID: 25348783)
Anal Biochem. 1976 May 7;72:248-54. (PMID: 942051)
Int J Biol Markers. 2010 Jan-Mar;25(1):1-11. (PMID: 20155712)
Proteome Sci. 2014 Jun 09;12:32. (PMID: 24944525)
Sci Transl Med. 2012 Mar 28;4(127):127rv3. (PMID: 22461644)
Rapid Commun Mass Spectrom. 2008;22(6):905-8. (PMID: 18293430)
J Proteome Res. 2009 Feb;8(2):942-57. (PMID: 19093873)
Nature. 2008 Jul 24;454(7203):436-44. (PMID: 18650914)
J Clin Invest. 2006 Mar;116(3):607-14. (PMID: 16511593)
J Immunol. 2000 Apr 1;164(7):3480-6. (PMID: 10725700)
Biochim Biophys Acta. 2013 Jan;1835(1):100-9. (PMID: 23123827)
Cancer Res. 2004 Nov 1;64(21):7686-9. (PMID: 15520170)
Proteome Sci. 2015 Jan 29;13(1):2. (PMID: 25653573)
Bioessays. 2009 Nov;31(11):1245-54. (PMID: 19795409)
فهرسة مساهمة: Keywords: 2-D DIGE/MS; LC-MS/MS; non-invasive biomarker; prostate cancer; proteomics; urine
تواريخ الأحداث: Date Created: 20171230 Latest Revision: 20220408
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC5874760
DOI: 10.3390/proteomes6010001
PMID: 29286311
قاعدة البيانات: MEDLINE
الوصف
تدمد:2227-7382
DOI:10.3390/proteomes6010001